Skip to main content

Table 1 Patient characteristics

From: Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death

Patient sample ALL5 ALL6 ALL10 ALL12 ALL16 ALL17 ALL18 ALL19 ALL20 ALL 21
Age (years.months) 14.5 5.0 15.6 3.4 2.8 3.2 6.5 7.5 7.4 11.7
Sex Female Female Female Female Male Male Male Male Male Male
Sample from relapse No Yes No No No No No No No No
Immunophenotype Common-B Common-B Common-B Pre-B Pre-B Pre-B Pre-B Pre-B Pre-B Pre-B
Cytogenetics t(9;22) Normal karyotype t(12;21)t(5;17) t(12;21)(p13;q22) 47 ~ 48,XY,+X,i(21)(q10),+ i(21)(q10),[cp9]/46,XY[1] 46 XY, - 21c t(12,21) 44, X,-Y,t(4;14) (q25;q32 46,XY,t(1;19)(q(23;p13)[2]/46,XY[23] t(12;21)(p13;q22)
Residual disease at day 15 42 × 10-2 Not performed 30 × 10-2 1.1 × 10-2 3.2 × 10-3 8.9 × 10-3 8 × 10-3 No MRD 5 x 10-3 No MRD
Residual disease at day 29 27 × 10-2 No MRD 7.3 × 10-3 3 × 10-4 No MRD 9 × 10-4 5 × 10-4 No MRD No MRD No MRD
  1. MRD: minimal residual disease.